INTRODUCTION: Traumatic spinal cord injury (SCI) causes severe and permanent functional deficits, due to the primary mechanical insult, followed by secondary tissue degeneration. The direct damage is followed by a second phase of tissue degeneration, which may take place over a period of weeks or even months, causing neuronal and axonal destruction. A key mediator of this process is an acute and robust inflammatory response, which involves the synthesis and release of chemokines and cytokines, and a coordinated recruitment of circulating leucocytes, as well as microglia, from the CNS parenchyma. The search for a 'cure' for SCI has yet to produce a convincingly efficacious treatment that improves the outcome for patients. AREAS COVERED: This review explores the experimental studies describing the beneficial effects of PPAR receptor modulators in spinal cord trauma. EXPERT OPINION: Because of safety issues and limited data, PPAR agonists are not yet included in SCI-related treatment strategies. PPAR agonists for specific isoforms (α, β/δ and γ) have demonstrated both anti-inflammatory and immunomodulatory properties. Pharmacological activation of PPAR can be considered as a multi-faceted therapeutic target, due to its anti-inflammatory/antioxidant/anti-excitotoxic/pro-energetic profile, reported in some neurological and inflammatory-related diseases.

Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury.

ESPOSITO, EMANUELA;CUZZOCREA, Salvatore
2011

Abstract

INTRODUCTION: Traumatic spinal cord injury (SCI) causes severe and permanent functional deficits, due to the primary mechanical insult, followed by secondary tissue degeneration. The direct damage is followed by a second phase of tissue degeneration, which may take place over a period of weeks or even months, causing neuronal and axonal destruction. A key mediator of this process is an acute and robust inflammatory response, which involves the synthesis and release of chemokines and cytokines, and a coordinated recruitment of circulating leucocytes, as well as microglia, from the CNS parenchyma. The search for a 'cure' for SCI has yet to produce a convincingly efficacious treatment that improves the outcome for patients. AREAS COVERED: This review explores the experimental studies describing the beneficial effects of PPAR receptor modulators in spinal cord trauma. EXPERT OPINION: Because of safety issues and limited data, PPAR agonists are not yet included in SCI-related treatment strategies. PPAR agonists for specific isoforms (α, β/δ and γ) have demonstrated both anti-inflammatory and immunomodulatory properties. Pharmacological activation of PPAR can be considered as a multi-faceted therapeutic target, due to its anti-inflammatory/antioxidant/anti-excitotoxic/pro-energetic profile, reported in some neurological and inflammatory-related diseases.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/1916413
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 28
social impact